TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 to 65 years of age (both inclusive), at the time of informed consent~* Participants diagnosed with RRMS according to McDonald criteria 2010~* Participants have discontinued treatment with dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), glatiramer acetate (Copaxone®), intramuscular IFNβ-1a (Avonex®), pegylated interferon (Plegridy®), subcutaneous IFNβ-1b (Betaferon®) or fingolimod (Gilenya®) within 6 months prior to Visit 1~  * Currently treated with Rebif using RebiSmart 2.0, for a maximum of 6 months prior to Visit 1~ * Participants have a score on the Expanded Disability Status Scale (EDSS) between 0 to 5.0 inclusive~ * Participants willing and able to give informed consent.~Exclusion Criteria:~* Participants have known planned surgical procedures at the time of the informed consent that will prevent adherence to treatment with Rebif through RebiSmart 2.0~* Participants diagnosed with primary progressive, secondary progressive, or progressive relapsing MS~* pregnant or lactating, or planning to become pregnant subjects~* In the opinion of the Investigator has significant renal or hepatic impairment or other significant disease (e.g., cognitive or visual impairment) that would compromise adherence and completion of the study~* Reports any reason that he/she cannot complete the 1 year study~* Participants have a history of hypersensitivity to natural or recombinant interferon, or any other component of the formulation~* Participants who contraindicated for the treatment with subcutaneous IFNβ-1a therapy as per summary of product characteristics or currently approved specific country product information~* Participants have any other factor that in the opinion of the Investigator would make the subject unsuitable for participation in this study~* Participants have significant psychiatric symptoms that, in the opinion of the Investigator, would impact patient ability to comply with treatment recommendations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lower Extremity Venous Hemodynamics in Obese Patients Without Clinically Significant Venous Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-60 years old~* BMI within one of three strata (Normal: 18.5-24.9, Obese: 30.0-39.9, Morbidly Obese: ≥ 40)~Exclusion Criteria:~* Prior diagnosis of chronic venous insufficiency or venous stasis ulceration~* Prior diagnosis of lymphedema~* Significant lower extremity edema as determined by study investigators. Lipidemia (in the absence of venous or lymphatic related edema) is acceptable.~* Varicose veins (subcutaneous dilated vein \> 3 mm in diameter measured in upright position). Subjects with telangiectasias and/or mild reticular veins will be eligible (CEAP C1)~* Patients who have been prescribed compression stockings by a health care provider at any time in the past, aside from prophylactic use during prior hospitalization to prevent VTE~* Patients who have undergone any procedure for treatment of lower extremity varicose veins, including: sclerotherapy, venous ablation, phlebectomy, or a stripping procedure~* History of DVT or SVT~* Pregnancy~* Active malignancy~* Documented hypercoagulable state~* Body weight exceeds weight limit of the venous air plethysmograph chair equipment (approximately 375 lbs)~* Clinical diagnosis of lower extremity peripheral arterial disease or abnormal ankle-brachial index (ABI) in either lower extremity~* History of surgical intervention involving pelvis or lower extremities~* Pelvic or lower extremity radiation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Normal Body-Mass (Type: None): BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
- Obese Body-Mass (Type: None): BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
- Morbidly Obese Body-Mass (Type: None): BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Children's Nail Bed Injuries : Study of the Efficacy of the Simple Relocation of Nail Plate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age under 18 yo~* nail bed injuries and/or nail matrix~* nail plate \> 30% of the surface comparing the opposite side~* one or more digits~* signature of the 2 parents~* social security~Exclusion Criteria:~* loss of more than 30% of the surface of the nail bed~* Multiples lesions: nerve injury, tendon, fracture or luxation without indication of osteosynthesis, loss of skin with indication of a flap~* osteosynthesis of the distal phalanx~* injuries by bite~* previous pathology of the nail~* contraindication of Lidocaine, bicarbonate de sodium, Kalinox, Biseptine, Vicryl rapide, Adaptic~* no information possible~* pregnancy~* breastfeeding~* other inclusion in another study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- relocation of nail plate (Type: EXPERIMENTAL): the simple relocation of the nail plate in nailbed injuries in paediatric population

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosed with hematological diseases.~2. recipients of allogeneic peripheral blood stem cell transplantation.~3. new onset of grade II\~IV acute graft versus host disease within 100 days post-transplantation.~exclusion criteria:~1. recipients of second allogeneic stem cell transplant.~2. acute GVHD induced by donor lymphocyte infusion, interferon.~3. received treatment other than steroid before enrollment.~4. overlap GVHD syndrome.~5. pregnant or breast-feeding women.~6. absolute neutrophil count (ANC) \<0.5×10e9/L or platelet count (PLT) \< 20×10e9/L~7. non-GVHD related liver dysfunction: glutamic pyruvic transaminase\>= 4 times of upper normal limit, direct bilirubin \>= 4 times of upper normal limit~8. renal dysfunction: creatinine clearance \< 15 mL/min or glomerular filtration rate\< 15 mL/min~9. uncontrolled infection~10. human immunodeficiency virus infection~11. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.~12. relapse of primary malignant hematological diseases, or graft rejection.~13. allergic history to Janus kinase inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- combination therapy (Type: EXPERIMENTAL): There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~1. Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~2. Ruxolitinib oral tablet, 5\~10mg bid orally, for at least 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* C. difficile-associated diarrhea at the time of enrollment~* 18 years old and up~* Ability to take oral medications~* Negative urine pregnancy test for women of childbearing age~* Must have the ability to understand and the willingness to provide a written informed consent to participate in the study~Exclusion Criteria:~* History of known allergy to silicates~* Patients with signs of toxic megacolon, peritonitis, pseudomembranous colitis or bowel perforation~* Patients with hypotension (systolic blood pressure \< 90 mm Hg) or septic shock requiring pressors~* Patients with other known causes of diarrhea or colitis~* Pregnancy or lactation~* History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up~* Participation in any other study where the subject is actively taking investigational medication within the last 30 days~* More than 5 doses of metronidazole or oral vancomycin prior to starting on study drug for the current C. difficile diagnosis. Administration of metronidazole or oral vancomycin for treatment of prior C. difficile diagnosis is not exclusionary as some patients may be experiencing a relapse of C. difficile.~* Any other antibiotic, toxin-binding agent or fecal transplant used for the treatment of C. difficile prior to or added to the subject's standard-of-care treatment regimen. Use of intravenous vancomycin is not exclusionary.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label CASAD (Type: EXPERIMENTAL): Treatment with CASAD for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SubQStim: A Post-market Study of Subcutaneous Nerve Stimulation in Failed Back Surgery Syndrome (FBSS) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provides written Patient Informed Consent/Patient Information Sheet prior to study-related activities being conducted~2. ≥ 18 years of age at time of informed consent~3. Willing and available to attend visits as scheduled and to comply with the study protocol~4. Willing and able to undergo assessments as part of the evaluation for eligibility and endpoints~5. Willing and able to use the external neurostimulator, recharging equipment (if applicable), and patient programmer per the schedule required by the protocol~6. Diagnosed with FBSS (i.e.):~   * Has had persistent pain for 6 months following most recent anatomically correct, successful surgery AND~  * There are no further therapeutic surgical options available as assessed by appropriate investigation~7. Back pain is considered intractable and has been adequately treated (failed an appropriate trial of at least 3 different classes of back pain treatments (pharmaceutical and/or non-pharmaceutical))~8. Is an appropriate implant candidate for the SQS system~Exclusion Criteria:~1. Has been or is currently being treated with spinal cord stimulation, subcutaneous nerve stimulation, peripheral nerve stimulation or an implantable intrathecal drug delivery system~2. Evidence of an active disruptive psychiatric disorder that is significant enough to impact the perception of pain, compliance to intervention and/or ability to evaluate treatment outcome, as determined by the investigator~3. Has a pain condition unrelated to FBSS that is severe enough to overshadow the FBSS pain in the opinion of the investigator~4. Spinal instability or anatomic compression that requires further surgery~5. Spinal fusion at more than 3 vertebral levels~6. Currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study~7. Allergic or has shown hypersensitivity to any materials of the device system which come in contact with the body~8. History of coagulation disorder or lupus erythematosus~9. Involved in current litigation regarding back pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SQS plus OMM (Type: EXPERIMENTAL): subcutaneous nerve stimulation plus optimized medical management
- OMM (Type: ACTIVE_COMPARATOR): optimized medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: X-82 to Treat Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in one or both eyes for at least 6 months prior to joining the study and has required at least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater than 6 weeks for the past two injections in the eye that is selected to be the study eye.~* Must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-VEGF injection at Screening Visit 1~* Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25 letters (20/320) or better in both eyes~Exclusion Criteria:~* Previous vitrectomy to the study eye within 30 days of Screening Visit 1~* Choroidal neovascularization (CNV) due to causes other than AMD~* Proliferative diabetic retinopathy in either eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 50 mg of X-82 plus ivt anti-VEGF prn (Type: EXPERIMENTAL): Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
- 100 mg of X-82 plus ivt anti-VEGF prn (Type: EXPERIMENTAL): Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
- 200 mg of X-82 plus ivt anti-VEGF prn (Type: EXPERIMENTAL): Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
- Placebo plus ivt anti-VEGF prn (Type: PLACEBO_COMPARATOR): Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* a child \< 5 years of age being treated for acute gastroenteritis within 72 hours prior to evaluation in the study hospitals.~* outpatient children \< 5 years of age submitted for treatment of acute gastroenteritis within 72 hours prior to evaluation in the study clinics.~Exclusion Criteria:~* none specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Brazilian Children With Rotavirus Gastroenteritis (Type: None): Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tracking of Lipid Lowering Therapy in Jordan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~1. Adults aged 18 years or old.~2. Presence of atherosclerotic cardiovascular disease on lipid-lowering therapy.~3. LDL-C \> 70mg/dl.~4. Willingness to sign an informed consent.~Exclusion criteria~1. Life-threatening disease with limited survival.~2. Unwillingness to sign an informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with ASCVD (Type: None): Patients with ASCVD on statins and LDL-C more than 70 mg/dl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post Roux-n-Y gastric bypass (RYGB) surgery and sleeve gastrectomy (SG) patients who underwent surgery \>1 and \<15 years ago in the Cleveland surrounding area~* Age 20-75 years of age~* Type II Diabetes Mellitus (D2M) diagnosis (history, medication usage, biochemical criteria) prior to and after surgery; after surgery, defined by a single HbA1c of greater or equal to 6.5% at consent and screening.~* Metformin patients must have an HbA1c greater than or equal to 6.5% but less than or equal to 10% at randomization; for diet controlled patients (i.e. not on any T2D medication), HbA1c must be greater than or equal to 6.5% at randomization.~* Patient reporting of improvement in T2D status or objective improvements in T2D status at any time post-surgery.~* estimated glomerular filtration rate (eGFR) ≥ 60mL/min prior to randomization~* Has the ability and willingness to provide informed consent.~* Is able to understand the options and to comply with the requirements of each program~* Female subject agrees to have a serum pregnancy test at screening. A negative serum pregnancy test result is required prior to randomization.~* Female patients must agree to use a reliable method of contraception for 6 months or duration of intervention~* Patients taking an anti-diabetic medication, except insulin, are eligible and must agree to washout for 8 weeks prior to the randomization visit.~Exclusion Criteria:~* Type 1 diabetes indicated by history of diabetic ketoacidosis and lack of remission in response to bariatric surgery~* Other post bariatric procedures (banding, duodenal switch, biliopancreatic diversion)~* Current use of insulin.~* End organ diabetic complications (renal failure, cardiomyopathy, severe neuropathy/foot ulcers)~* Documented severe or unstable depression/anxiety or eating disorder that would not enable patient to adhere to anti-diabetic treatment~* Clinical contraindications to use canagliflozin, i.e., history of bladder cancer, Child-Pugh class C

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug (canagliflozin) (Type: ACTIVE_COMPARATOR): Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Training of Arms to Reduce Pain With Peripheral Venous Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned neoadjuvant or adjuvant chemotherapy via intravenous peripheral venous cannula placed under ultrasound guidance~* PVC insertion is performed in the DROP-IN outpatient clinic, Department of Anesthesiology, Vejle Hospital, at least four times~* The patient has provided written and orally informed consent~* The patient must be cognitively well preserved and able to understand information~Exclusion Criteria:~* Patients who cannot read and understand Danish~* Patients \<18 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Training group (Type: EXPERIMENTAL): None
- Normal care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues